

Appendix D: Source references for estimates used

Table 2 (D): Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in Europe

Countries and territories	IDU prevalence (%)			2007 IDU population			HIV prevalence (%)		
	Lower	Mid	Upper	Lower	Mid	Upper	Lower	Mid	Upper
Eastern Europe									
Armenia	--	(1)	--	--	(1)	--	(1, 2)	(1, 2)	(2)
Azerbaijan	--	(3, 4)	--	--	(3, 4)	--	(5)	(5)	(5)
Belarus	--	(6)	--	--	(6)	--	--	(6)	--
Bosnia & Herzegovina	--	(7)	--	--	--	--	--	(8)	--
Bulgaria	(9)	(9)	(9)	(9)	(9)	(9)	--	(10)	--
Croatia	--	(8)	--	--	--	--	--	(10)	--
Czech Republic	(11)	(11)	(11)	(11)	(11)	(11)	(10)	(10)	(10)
Estonia	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Georgia	(12)	(12, 13)	(13)	(12)	(12, 13)	(13)	(12)	(12, 13)	(13)
Hungary	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Latvia	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Lithuania	--	(14)	--	--	(14)	--	--	(10)	--
Moldova	--	(8)	--	--	(8)	--	--	(15)	--
Poland	(10)	(10)	(10)	(10)	(10)	(10)	--	(10)	--
Romania	--	(16, 17)	--	--	--	--	--	(10)	--
Russian Federation	--	(3)	--	--	(3)	--	(18)	(18)	(18)
Slovakia	(11)	(11)	(11)	(11)	(11)	(11)	--	(10, 19, 20)	--
Ukraine	(21)	(21)	(21)	--	--	--	--	(22)	--
Western Europe:									
Albania	--	(23)	--	--	--	--	--	(10)	--
Andorra	--	(23)	--	--	--	--	--	(10)	--
Austria	(10)	(10)	(10)	(10)	(10)	(10)	--	(10)	--
Belgium	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Denmark	(10)	(10)	(10)	(10)	(10)	(10)	--	(10)	--
Finland	(10)	(10)	(10)	(10)	(10)	(10)	--	(10)	--
France	--	(10)	--	--	(10)	--	--	(10)	--
Germany	(10)	(10)	(10)	(10)	(10)	(10)	--	(10)	--
Greece	(11)	(11)	(11)	(11)	(11)	(11)	(10)	(10)	(10)
Iceland	--	(23)	--	--	--	--	--	(23)	--
Ireland	(10)	(10)	(10)	(10)	(10)	(10)	--	(10)	--
Italy	--	(10)	--	--	(10)	--	--	(24)	--
Liechtenstein	--	--	--	--	--	--	--	--	--
Luxembourg	--	(10, 25)	--	--	(10, 25)	--	--	(10)	--
Macedonia FYR	--	(23)	--	--	--	--	--	(23)	--
Malta	(10)	(10)	(10)	(10)	(10)	(10)	--	(10)	--

Monaco	--	(23)	--	--	--	--	--	(23)	--
Montenegro	--	(23)	--	--	--	--	--	(23)	--
Netherlands	(10)	(10)	(10)	(10)	(10)	(10)	--	(26)	--
Norway	(10, 27)	(10, 27)	(10, 27)	(10, 27)	(10, 27)	(10, 27)	--	(10)	--
Portugal	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)
San Marino	--	(23)	--	--	--	--	--	(23)	--
Serbia	--	(23)	--	--	--	--	--	(23)	--
Slovenia	--	(10)	--	--	(10)	--	--	(10)	--
Spain	--	(10)	--	--	(10)	--	--	(10)	--
Sweden	--	(10)	--	--	(10)	--	--	(10)	--
Switzerland	(10)	(10)	(10)	(10)	(10)	(10)	--	(10)	--
United Kingdom	(11)	(11)	(11)	(11)	(11)	(11)	(24, 28)	(24, 28)	(24, 28)

Table 3 (D): Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in Asia

	IDU prevalence (%)			2007 IDU population			HIV prevalence (%)		
	Lower	Mid	Upper	Lower	Mid	Upper	Lower	Mid	Upper
East and South East Asia:									
Brunei Darussalam	--	(29)	--	--	--	--	--	(30)	--
Cambodia	(31)	(31)	(31)	(31)	(31)	(31)	(31)		
China	(32)	(32)	(32)	(32)	(32)	(32)	(32)		
DPR Korea	--	--	--	--	--	--	--	--	--
Indonesia	(33)	(33)	(33)	(33)	(33)	(33)	(33)	(33)	(33)
Japan	--	(34)	--	--	(34)	--	--	(34)	--
Lao PDR	--	(35-37)	--	--	--	--	--	(38)	--
Malaysia	(39)	(39)	(39)	(39)	(39)	(39)	--	(40)	--
Mongolia	--	(41)	--	--	--	--	--	(41)	--
Myanmar	(42)	(42) (43)	(42)	(42)	(42)	(42)	(42)	(42)	(42)
Republic of Korea	--	(44)	--	--	--	--	--	(44)	--
Philippines	--	(45-47)	--	--	--	--	--	(45)	--
Singapore	--	(34)	--	--	--	--	--	(30)	--
Taiwan province of China	--	(48)	--	--	--	--	(48)	(48, 49)	(49)
Thailand	--	(50-52)	--	--	(50-52)	--	--	(53)	--
Timor Leste	--	(54)	--	--	--	--	--	--	--
Viet Nam	--	(55)	--	--	(55)	--	--	(56)	--
South Asia:									
Afghanistan	(57)	(57)	(57)	(57)	(57)	(57)	(58)	(58)	(58)
Bangladesh	(59)	(60, 61)	(59, 60)	(60)	(60)	(60)	(61)	(61)	(61)
Bhutan	--	(62)	--	--	--	--	--	--	--
India	(63)	(63)	(63)	(63)	(63)	(63)	--	(64)	--
Iran, Islamic Republic	--	(65)	--	--	(65)	--	(66)	(66)	(66)
Maldives	--	(67)	--	--	--	--	--	--	--
Nepal	(68)	(68)	(68)	(68)	(68)	(68)	--	(68)	--
Pakistan	(69)	(69)	(69)	(69)	(69)	(69)	(69, 70)	(69, 70)	(69, 70)
Sri Lanka	--	(44, 71, 72)	--	--	--	--	--	(72)	--
Central Asia:									
Kazakhstan	--	--	--	--	(3, 73, 74)	--	(73, 74)	--	(73, 74)
Kyrgyzstan	--	--	--	--	(73, 74)	--	(73, 74)	--	(73, 74)
Tajikistan	--	--	--	--	(73, 74)	--	(73, 74)	--	(73, 74)
Turkmenistan	--	(3)	--	--	--	--	--	(3)	--
Uzbekistan	--	(3, 73, 74)	--	--	(3, 73, 74)	--	(73-75)	--	(73, 74, 76)

Table 4 (D): Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in the Americas

Countries and territories	IDU prevalence (%)			2007 IDU population			HIV prevalence (%)		
	Lower	Mid	Upper	Lower	Mid	Upper	Lower	Mid	Upper
Antigua & Barbuda	--	(77)	--	--	--	--	--	(77)	--
Bahamas	--	(30, 77)	--	--	--	--	--	(30)	--
Barbados	--	(77)	--	--	--	--	--	(78)	--
Bermuda	--	(30)	--	--	--	--	--	--	--
Commonwealth of Puerto Rico	--	(79)	--	--	(79)	--	--	(80)	--
Cuba	--	--	--	--	--	--	--	(81)	--
Dominica	--	(77, 82)	--	--	--	--	--	(77)	--
Dominican Republic	--	(30)	--	--	--	--	--	(30)	--
Grenada	--	(77)	--	--	--	--	--	(77)	--
Haiti	--	(77, 82, 83)	--	--	--	--	--	(77, 84, 85)	--
Jamaica	--	(77)	--	--	--	--	--	(77, 86-88)	--
Saint Kitts & Nevis	--	(82)	--	--	--	--	--	(77)	--
Saint Lucia	--	(82)	--	--	--	--	--	(77)	--
Saint Vincent & Grenadines	--	(77)	--	--	--	--	--	(77)	--
Trinidad & Tobago	--	(89)	--	--	--	--	--	(77)	--
Latin America:									
Argentina	(90)	(90, 91)	(91)	(90)	(90, 91)	(91)	(91) (92)	(91, 92)	(91, 92)
Belize	--	(93)	--	--	--	--	--	(77, 93, 94)	--
Bolivia	--	(94)	--	--	--	--	--	(94)	--
Brazil	--	(95)	--	--	(95)	--	(90, 96-98)	(90, 96-98)	(90, 96-98)
Chile	--	(99)	--	--	(99)	--	--	(100, 101)	--
Colombia	--	(96)	--	--	--	--	(96)	(96)	(96)
Costa Rica	--	(30)	--	--	--	--	--	(30)	--
Ecuador	--	(30)	--	--	--	--	--	(30)	--
El Salvador	--	(94, 102)	--	--	--	--	--	(94, 102)	--
Guatemala	--	(94, 102)	--	--	--	--	--	(94, 102)	--
Guyana	--	(103)	--	--	--	--	--	--	--
Honduras	--	(104)	--	--	--	--	--	(94, 102, 104)	--
Mexico	--	(90, 105)	--	--	--	--	(106) (107)	(106)	(106, 107)
Nicaragua	--	(30)	--	--	--	--	--	(96)	--
Panama	--	(94, 102)	--	--	--	--	--	(94, 102)	--
Paraguay	--	(108, 109)	--	--	--	--	(108, 109)	(108, 109)	(108, 109)
Peru	--	(96)	--	--	--	--	--	(96)	--
Suriname	--	(30)	--	--	--	--	--	(110)	--
Uruguay	--	(111)	--	--	--	--	--	(90, 112)	--
Venezuela	--	(30)	--	--	--	--	--	(30)	--
Canada and the US:									
Canada	(113)	(113)	(113)	(113)	(113)	(113)	(114)	(114)	(114)
United States	(79)	(79)	(79)	(79)	(79)	(79)	(79, 115)	(79, 115)	(79, 115)

Table 5 (D): Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in Oceania

Countries and territories	IDU prevalence (%)			2007 IDU population			HIV prevalence (%)		
	Lower	Mid	Upper	Lower	Mid	Upper	Lower	Mid	Upper
Pacific Island States and Territories:									
American Samoa	--	--	--	--	--	--	--	--	--
Micronesia (Federated States of)	--	(116)	--	--	--	--	--	(116)	--
Fiji	--	(117)	--	--	--	--	--	(117, 118)	--
French Polynesia	--	(117)	--	--	--	--	--	(30)	--
Guam	--	(30)	--	--	--	--	--	(30)	--
Kiribati	--	(117, 119)	--	--	--	--	--	(117)	--
Marshall Islands	--	--	--	--	--	--	--	--	--
Nauru	--	--	--	--	--	--	--	--	--
New Caledonia	--	(30)	--	--	--	--	--	(30)	--
Palau	--	--	--	--	--	--	--	--	--
Papua New Guinea	--	(120, 121)	--	--	--	--	--	(122)	--
Samoa	--	(117)	--	--	--	--	--	(117)	--
Solomon Islands	--	(117)	--	--	--	--	--	(117)	--
Tonga	--	(117)	--	--	--	--	--	(117)	--
Tuvalu	--	--	--	--	--	--	--	--	--
Vanuatu	--	(117)	--	--	--	--	--	--	--
Australasia:									
Australia	(123)	(123)	(123)	(123)	(123)	(123)	--	(124)	--
New Zealand				(125)	(125)	(125)	--	(125)	--

Table 6 (D): Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in the Middle East and Africa

Countries and territories	IDU prevalence (%)			2007 IDU population			HIV prevalence (%)		
	Lower	Mid	Upper	Lower	Mid	Upper	Lower	Mid	Upper
Middle East and North Africa:									
Algeria	--	(126, 127)	--	--	--	--	--	(111, 127, 128)	--
Bahrain	--	(129)	--	--	--	--	(129)	(129)	(129)
Cyprus	(11)	(11)	(11)	(11)	(11)	(11)	--	(130)	--
Egypt	--	(128, 131-134)	--	--	--	--	(135)	(135)	(135)
Iraq	--	(30)	--	--	--	--	--	--	--
Israel	--	(136)	--	--	--	--	(136) (137)	(136)	(136)
Jordan	--	(128, 138, 139)	--	--	--	--	--	(129, 138)	--
Kuwait	--	(128, 129)	--	--	--	--	--	(129)	--
Lebanon	--	(140)	--	--	--	--	--	(128, 140)	--
Libyan Arab Jamahiriya	--	(132)	--	--	(132)	--	--	(141)	--
Morocco	--	(141, 142)	--	--	--	--	--	(141)	--
Occupied Palestinian Territories	--	(132)	--	--	--	--	--	(128)	--
Oman	--	(128)	--	--	--	--	(128)	(128, 141)	(141)
Qatar	--	(30, 132)	--	--	--	--	--	(30, 132)	--
Saudi Arabia	--	(128, 143)	--	--	--	--	--	(128)	--
Sudan	--	(30)	--	--	--	--	--	(128)	--
Syrian Arab Republic	--	(132)	--	--	--	--	--	(128)	--
Tunisia	--	(128, 132, 144)	--	--	--	--	--	(144)	--
Turkey	--	(10)	--	--	--	--	(145)	(10, 145)	(10)
United Arab Emirates	--	(132)	--	--	--	--	--	--	--
Yemen	--	(132)	--	--	--	--	--	--	--
Sub-Saharan Africa:									
Angola	--	--	--	--	--	--	--	--	--
Benin	--	--	--	--	--	--	--	--	--
Botswana	--	--	--	--	--	--	--	--	--
Burkina Faso	--	--	--	--	--	--	--	--	--
Burundi	--	--	--	--	--	--	--	--	--
Cameroon	--	--	--	--	--	--	--	--	--
Cape Verde	--	--	--	--	--	--	--	--	--
Central African Republic	--	--	--	--	--	--	--	--	--
Chad	--	--	--	--	--	--	--	--	--
Comoros	--	--	--	--	--	--	--	--	--
Cote d'Ivoire	--	(30)	--	--	--	--	--	--	--
Democratic Republic of the Congo	--	--	--	--	--	--	--	--	--
Djibouti	--	(30)	--	--	--	--	--	(30)	--
Equatorial Guinea	--	--	--	--	--	--	--	--	--
Eritrea	--	--	--	--	--	--	--	--	--
Ethiopia	--	--	--	--	--	--	--	--	--

Gabon	--	(30)	--	--	--	--	--	--	--
Gambia	--	--	--	--	--	--	--	--	--
Ghana	--	(30)	--	--	--	--	--	--	--
Guinea	--	--	--	--	--	--	--	--	--
Guinea-Bissau	--	--	--	--	--	--	--	--	--
Kenya	(146)	(146)	(147)	(146) (148)	(146)	(147) (148)	(149)	(149, 150)	(150)
Lesotho	--	--	--	--	--	--	--	--	--
Liberia	--	--	--	--	--	--	--	--	--
Madagascar	--	--	--	--	--	--	--	--	--
Malawi	--	(151)	--	--	--	--	--	--	--
Mali	--	--	--	--	--	--	--	--	--
Mauritania	--	--	--	--	--	--	--	--	--
Mauritius	(152, 153)	(152, 153)	(152, 153)	(152, 153)	(152, 153)	(152, 153)	--	(152, 153)	--
Mozambique	--	--	--	--	--	--	--	--	--
Namibia	--	--	--	--	--	--	--	--	--
Niger	--	--	--	--	--	--	--	--	--
Nigeria	--	(154, 155)	--	--	--	--	(154) (155)	(154)	(154, 155)
Republic of the Congo	--	--	--	--	--	--	--	--	--
Rwanda	--	--	--	--	--	--	--	--	--
Sao Tome & Principe	--	--	--	--	--	--	--	--	--
Senegal	--	(30)	--	--	--	--	--	--	--
Seychelles	--	--	--	--	--	--	--	--	--
Sierra Leone	--	--	--	--	--	--	--	--	--
Somalia	--	--	--	--	--	--	--	--	--
South Africa	--	(156)	--	--	(156)	--	(157)	(157, 158)	(158)
Swaziland	--	--	--	--	--	--	--	--	--
Togo	--	--	--	--	--	--	--	--	--
Uganda	--	(30)	--	--	--	--	--	--	--
United Republic of Tanzania	--	(131, 159-162)	--	--	--	--	--	(159, 160, 163)	--
Zambia	--	(30)	--	--	--	--	--	--	--
Zimbabwe	--	--	--	--	--	--	--	--	--

References

1. Markosyan KM, Kocharyan A, Potosyan A. Meeting the challenge of injection drug use and HIV in Armenia. *Health & Human Rights*. 2006;9(1):128-51.
2. Republic of Armenia. HIV/AIDS Epidemic in the Republic of Armenia. In: National Centre for AIDS Prevention, editor.; 2007.
3. AIDS Projects Management Group. Measuring Coverage of HIV Prevention and Care for Injecting Drug Users: Draft Final Report. Sydney: AIDS Project Management Group.; 2007.
4. Nasibov R. Rapid assessment of situation on intravenous drug use related HIV/AIDS in Azerbaijan. The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro; 2005.
5. World Health Organization. Regional Office for Europe. HIV sentinel surveillance in high-risk groups in the Russian Federation, Azerbaijan Republic and the Republic of Moldova: report on a WHO project 1 April 2003 - 31 March 2004. Copenhagen: WHO Regional Office for Europe.; 2004.
6. AIDS Projects Management Group. Assessment of Phase I harm reduction projects funded by Global Fund to fight AIDS, Tuberculosis and Malaria HIV/AIDS grant in Belarus. Sydney: AIDS Projects Management Group; 2006.
7. The Country Coordinating Mechanism for the Global Fund in Bosnia-Herzegovina. Coordinated National Response to HIV/AIDS & Tuberculosis in a war-torn and highly stigmatised setting. Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria; 2005. p. 89.
8. United Nations Office on Drugs and Crime. Audit on the number of injecting drug users in Central and Eastern Europe and Central Asia. New York; 2003.
9. National Focal Point for Drugs and Drug Addictions. Annual Report on the state of the drugs problem in Bulgaria 2006. Sofia: National Drug Council; 2006 October 2006.
10. European Monitoring Centre for Drugs and Drug Addiction. 2007 Annual Report: The State of the Drugs Problem In Europe. Lisbon: EMCDDA; 2007.
11. European Monitoring Centre for Drugs and Drug Addiction. Estimates of Injecting Drug use in Europe. 2008.
12. Akhobadze T. Email "Drug use prevalence data for Georgia". In: Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW, editor. Response to request for data ed. Tbilisi: IHRD: Open Society Georgia Foundation.; 2008.
13. Stvilia K, Tsertsvadze T, Sharvadze L, Aladashvili M, del Rio C, Kuniholm MH, et al. Prevalence of hepatitis C, HIV, and risk behaviors for blood-borne infections: a population-based survey of the adult population of T'bilisi, Republic of Georgia,. *J Urban Health*.,. 2006 Mar;83(2):289-98.
14. Drug Control Department. 2007 National Report (2006 data) to the EMCDDA by the Reitox National Focal Point: Lithuania New Development, Trends and In-depth Information on Selected Issues: Government of the Republic of Lithuania.; 2007.
15. Kelly JA, Amirkhania YA. The newest epidemic: a review of HIV/AIDS in Central and Eastern Europe. *International Journal of STD & AIDS*. 2003 Jun;14(6):361-71.
16. Iliuta C, Bocioc F, Militaru C. Demonstrating the impact of civil society involvement in the target setting process for universal access. Vilnius: Central and Eastern European Harm Reduction Network; 2007.
17. European Monitoring Centre for Drugs and Drug Addiction & Reitox National Focal Point. Romania: Drug Situation 2001. Bucharest: EMCDDA; 2002.
18. Borschevskaya V, Tumano M. Country Report of the Russian Federation on the Implementation of the Declaration of Commitment on HIV/AIDS (UNGASS) January-

December 2005. Moscow: Federal Services for Surveillance of Consumer Rights and Welfare of Russian Federation,; 2006 March 15 2006.

19. Holt E. Slovakia has kept AIDS out despite money problems. *The Lancet*. 2004 May 22, 2004;363:4.

20. Kiššová Le. Report for the EMCDDA – the REITOX1 National Focal Point in the Slovak Republic: The State of Drug Addiction and Drug Control in the Slovak Republic Developments, trends, and selected issues concerning the drug problem in the Slovak Republic. In: The Government Office of the Slovak Republic, The General Secretariat of the Ministerial Board for Drug Addiction and Drug Control, National Monitoring Centre for Drugs, editors.; 2005. p. 227.

21. Balakiryeva OM, Gusak LM, Dovbakh HV, Lavryenov OO, Paniotto VI, Petrenko TV, et al. Evaluation of the size of most-at-risk-populations vulnerable to HIV infection in Ukraine: analytical report based on the research results. Kyiv: International HIV/AIDS Alliance in Ukraine; 2006.

22. Ministry of Health of Ukraine. Ukraine: National Report on Monitoring Progress Towards the UNGASS Declaration of Commitment on HIV/AIDS - Reporting Period: January 2006 - December 2007. Kyiv: Ministry of Health, Ukraine.; 2008.

23. Donoghoea MC, Bollerup AR, Lazarus JV, Nielsen S, Matic S. Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002–2004. *International Journal of Drug Policy*. 2007;18(4):271–80.

24. EuroHIV. HIV/AIDS Surveillance in Europe. End-year report 2006. Saint Maurice: Institut de Veille sanitaire/French Institute for Public Health Surveillance, European Centre for the Epidemiological Monitoring of AIDS (EuroHIV); 2007 December 2007. Report No.: 76.

25. European Monitoring Centre for Drugs and Drug Addiction. National Prevalence Estimates of Problem Drug Use in the European Union, 1995-2000. . Lisbon: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2003.

26. EuroHIV. HIV/AIDS Surveillance in Europe. End-year report 2006. Saint Maurice: Institut de veille sanitaire; 2007. Report No.: 76.

27. Bretteville-Jensen A, Amundsen E. Quantification of intravenous drug use in Norway. Oslo: Norwegian Institute for Alcohol and Drug Research; 2006.

28. Wiessing L. Email "HIV prevalence in the UK". In: Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW, editor. Response to request for data ed. Lisbon: European Monitoring Centre for Drugs and Drug Addiction 2008.

29. United Nations Office on Drugs and Crime. Patterns and Trends of Amphetamine-Type Stimulants (ATS) and Other Drugs of Abuse in East Asia and the Pacific 2006. Bangkok; 2007 June 2007.

30. Ball AL, Rana S, Dehne KL. HIV Prevention among Injecting Drug Users: Responses in Developing and Transitional Countries. *Public Health Reports*. 1998 June;113(1):12.

31. National Authority for Combating Drugs. Report on Illicit Drug Data and Routine Surveillance Systems in Cambodia 2006. Phnom Penh: Royal Government of Cambodia; 2007.

32. Lu F, Wang N, Wu Z, Sun X, Rehnstrom J, Poundstone K, et al. Estimating the number of people at risk for and living with HIV in China in 2005: methods and results. *Sexually Transmitted Infections*. 2006 Jun;82(S3):S87-91.

33. Komisi Penanggulangan AIDS. National report on estimates of adults vulnerable to HIV and infection in Indonesia, 2006. Jakarta: National AIDS Commission Indonesia; 2007.

34. United Nations Office on Drugs and Crime. Patterns and Trends of Amphetamine-Type Stimulants (ATS) and Other Drugs of Abuse in East Asia and the Pacific 2005. Bangkok; 2006 June 2006.

35. Hidalgo E. Establishing the LCDC Drug Information System: Lao People's Democratic Republic 2005. Vientiane: UNODC Lao Country Office/Lao National Commission for Drug Abuse and Control and Supervision; 2005.
36. The United Nation Office for Control Drug and Crime, The Lao National Commission for the Drug Control and Supervision, The Centre for HIV/AIDS and STI, The Burnet Institute. Drug use and HIV risk: Khamkeuth District (Bolikhamxay), Sing District (Luang Namtha), Khua District (Phongsaly), Lao PDR. Vientiane: The United Nation Office for Control Drug and Crime, The Lao National Commission for the Drug Control and Supervision, The Centre for HIV/AIDS and STI, The Burnet Institute, ; 2005 23 June-27 July 2005.
37. Family Health International. Lao People's Democratic Republic Final Report 1997-2007: USAID;; 2007 July 2007.
38. Phimpachanh C, Sayabounthavong K. The HIV/AIDS/STI situation in Lao People's Democratic Republic. AIDS Education and Prevention. 2004 Jun;16(SA):91-9.
39. Reid G, Kamarulzaman A, Sran SK. Rapid Situation Assessment of Malaysia: The Centre for Harm Reduction; 2004.
40. Government Malaysia. Country Report Malaysia: United Nations General Assembly Special Session on HIV/AIDS Monitoring the Declaration of Commitment on HIV/AIDS 2005.
41. World Health Organization. A Rapid Assessment and Response to HIV and Drug Use in Mongolia - Draft report. Manila: WHO Regional Office for the Western Pacific;; 2006.
42. Miller A. Email "IDU figures Myanmar". In: Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW, editor. Response to request for data ed. Rangoon: Resource Mobilization and Technical Assistance Coordination Officer, UNAIDS Myanmar;; 2008.
43. United Nations Regional Task Force on Injecting Drug Use and HIV/AIDS in Asia and the Pacific. Myanmar – United Nations Regional Task Force on Injecting Drug Use and HIV/AIDS in Asia and the Pacific Baseline Assessment Dec 2006 2006.
44. Reid G, Costigan G. Revisiting "The Hidden Epidemic": A Situation Assessment of Drug Use in Asia in the context of HIV/AIDS,. Melbourne: The Centre for Harm Reduction, The Burnet Institute Australia; 2002 January 2002.
45. National Epidemiology Center. 2005 Integrated HIV Behavioral and Serologic Surveillance Findings Summary Report. Manila: Department of Health;; 2005.
46. Global Fund. Proposal Form, Scaling Up HIV Prevention, Treatment, Care and Support Through Enhanced Voluntary Counselling and Testing and Improved Blood Safety Strategies. Philippines; 2006. p. 153.
47. Philippine National AIDS Council. Country Report of the Philippines. Manila: Philippine National AIDS Council (PNAC);; 2005.
48. Centres for Disease Control R.O.C. (Taiwan). Populations Vulnerable to HIV Infection. CDC Taiwan 2007 23 November 2007 [cited 2007 24 November]; Available from: <http://www.cdc.gov.tw/content.asp?Cultem=7423>
49. Cheng SH, Chu F-Y, Chiang S-C, Liu Y-R, Wu Z-Y. Prevalence of hepatitis B, C, D, and human immunodeficiency virus infections among substance users in Taiwan. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sydney; 2007.
50. Global Fund. Grant Performance Report Preventing HIV/AIDS and Increasing Care and Support for Injection Drug Users in Thailand. Thailand, : Raks Thai Foundation; 2007. p. 22.
51. Global Fund. Proposal Form: Preventing HIV/AIDS and Increasing Care and Support for Injection Drug Users in Thailand. Thailand: Raks Thai Foundation; 2003. p. 46.

52. Human Rights Watch. Not Enough Graves: The War on Drugs, HIV/AIDS, and Violations of Human Rights. New York; 2004.
53. World Health Organization. Scaling up Antiretroviral Treatment: Lessons Learnt from Thailand. Report of an external evaluation, 12-19 October 2004. New Delhi: WHO; 2007.
54. Devaney M, Reid G, Baldwin S. Situational analysis of illicit drug issues and responses in the Asia-Pacific region. Canberra: Burnet Institute: Centre for Harm Reduction and Turning Point Alcohol and Drug Centre; 2006.
55. Global Fund. Proposal Form Sixth Call for Proposals. Viet Nam; 2006. p. 123.
56. Ministry of Health. Results from the HIV/STI Intergrated Biological and Behavioral Surveillance (IBBS) in Viet Nam 2005-2006. Hanoi; 2007.
57. United Nations Office on Drugs and Crime. Afghanistan drug use survey 2005. Kabul; 2005 2005.
58. Todd CS, Abed AMS, Strathdee SA, Scott PT, Botros BA, Safi N, et al. HIV, Hepatitis C, and Hepatitis B Infections and Associated Risk Behavior in Injection Drug Users, Kabul, Afghanistan,. *Emerging Infectious Diseases*,. 2007 September 2007;;13(9):5.
59. Reddy A. Size Estimation of IDU in Bangladesh. Dhaka: Family Health International 2005.
60. Azim T, Chowdhury EI, Reza M, Faruque MO, Ahmed G, Khan R, et al. Prevalence of infections, HIV risk behaviors and factors associated with HIV infection among male injecting drug users attending a needle/syringe exchange program in Dhaka, Bangladesh. in press.
61. Azim T, Rahman M, Alam MS, Chowdhury IA, Khan R, Reza M, et al. Bangladesh moves from being a low-prevalence nation for HIV to one with a concentrated epidemic in injecting drug users. *International Journal of STD & AIDS*. 2008;19(May):327-31.
62. United Nations Office on Drugs and Crime: Regional Office for South Asia. Rapid Situation Response Assesment Bhutan Report - Draft. New Delhi,: UNODC Regional Office for South Asia; 2007.
63. Resource Centre for Sexual Health and AIDS (RCSHA). Report of the Expert Group on Size Estimation of Population with High Risk Behaviour for NACP-III Planning. New Delhi; 2006.
64. National AIDS Control Organization. HIV/AIDS epidemiological Surveillance & Estimation report for the year 2005: National AIDS Control Organization (NACO), Ministry of Health & Family Welfare, Government of India; 2006 April 2006.
65. Mokri A, Schottenfeld R. Drug Abuse and HIV Transmission in Iran— Responding to the Public Health Challenges. Tehran: Tehran University of Medical Sciences and the Iranian National Center for Addiction Studies, and Yale University School of Medicine; 2007.
66. Centre for Diseases Management. Islamic Republicof Iran Country Report on Monitoring of the United Nations General Assembly Special Session on HIV and AIDS: Office of the Under-secretary for Health, Ministry of Health and Medical Education, Centre for Diseases Management.; 2006.
67. The Foundation for Advancement of Self Help in Attaining Needs (FASHAN), Narcotics Control Board (NCB) of Maldives. Rapid Situation Assessment of Drug Abuse in Maldives 2003,. Male': Narcotics Control Board (NCB) of Maldives;; 2003.
68. National Centre for AIDS and STD Control. National Estimates of Adult HIV Infections, Nepal 2003. Kathmandu, Nepal Ministry of Health, His Majesty's Government of Nepal; 2004 March.
69. Ministry of Narcotics Control, Anti-Narcotics Force, United Nations Office on Drugs and Crime. Problem Drug Use in Pakistan: Results from the National Assesment: United Nations Office of Drugs and Crime;; 2007.

70. National AIDS Control Program. HIV Second Generation Surveillance in Pakistan: National Report Round 1. Islamabad: National AIDS control Program, Ministry of Health; 2005.
71. Kumar S. Injecting of pharmaceutical drugs in the South-Asia: A Review. Chennai; 2006. p. 8.
72. Fernando T, Bridger D. Email "re: Request for data on IDU and HIV prevalence". In: Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW, editor. Response to request for data ed. Colombo: UNAIDS Sri Lanka and the Maldives; 2008.
73. Niaz K. Email "re: Request for prevalence estimates and Sentinel Surveillance data". In: Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW, editor. Response to request for data ed. Tashkent: Regional Office in Central Asia, United Nations Office on Drugs and Crime; 2008.
74. Niaz K. Assessment of Problem Drug Use in Central Asia: UNODC/WHO Technical Consultation on Setting Targets for Universal Access to HIV Prevention, Treatment and Care for Injecting Drug Users (IDU) in Azerbaijan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan. Tashkent: UNODC, WHO; 2007 28 -30 May.
75. Niaz K. Re: Request for prevalence estimates and Sentinel Surveillance data. In: Secretariat of the Reference Group to the United Nations on HIV and injecting drug use, editor. Response to request for data ed. Tashkent, Uzbekistan: Regional Office in Central Asia, United Nations Office on Drugs and Crime; 2008.
76. Sanchez JL, Todd CS, Bautista CT, Botros BAE, Khakimov MM, Giyasova GM, et al. High HIV prevalence and risk factors among injection drug users in Tashkent, Uzbekistan, 2003-2004. *Drug and Alcohol Dependence*. 2006;82(S1):S15-S22.
77. CAREC. The Caribbean HIV/AIDS Epidemic and the Situation in Member Countries of the Caribbean Epidemiology Centre (CAREC): Caribbean Epidemiology Centre (CAREC) and Pan American Health Organization; 2007 February 2007.
78. World Health Organization. Epidemiological Fact Sheets on HIV/AIDS and Sexually Transmitted Infections: Barbados. Geneva: WHO; 2006.
79. Brady JE, Friedman SR, Cooper LF, Flom PL, Tempalski B, Gostnell K. Estimating the Prevalence of Injection Drug Users in the U.S. and in Large U.S. Metropolitan Areas from 1992 to 2002. *Journal of Urban Health: Bulletin of the New York Academy of Medicine*,. 2008;83(3):1099-3460.
80. Reyes J, C., Robles R, R., Colon H, M., Marrero C, A., Matos T, D., Calderon J, M., et al. Severe anxiety symptomatology and HIV risk behavior among Hispanic injection drug users in Puerto Rico. *AIDS & Behavior*. 2007 January;11(1):145-50.
81. World Health Organization. Approaches to the management of HIV/AIDS in Cuba. Geneva: World Health Organisation; 2004.
82. Inter-American Observatory on Drugs. Qualitative Research on Drug Use: Assessing Emerging Drug Trends in the Caribbean. Washington D.C.: Inter-American Observatory on Drugs (OID); 2004.
83. Hepburn MJ, Lawitz EJ. Seroprevalence of hepatitis C and associated risk factors among an urban population in Haiti. *BMC Gastroenterology*. 2004 Dec 14;4:31.
84. World Health Organization. Access to Antiretroviral Treatment and Care: The Experience of the HIV Equity Initiative, Cange, Haiti. Port-au-Prince: WHO; 2003.
85. Gaillard EM, Boulos LM, Andre Cayemittes MP, Eustache L, Van Onacker JD, Duval N, et al. Understanding the reasons for decline of HIV prevalence in Haiti. *Sexually Transmitted Infections*. 2006 Apr;82(S1):14-20.
86. Figueroa JP. An overview of HIV/AIDS in Jamaica: strengthening the response. *West Indian Medical Journal*. 2004 Oct;53(5):277-82.
87. Vickers IE, Alveranga H, Smikle MF. Clinical and epidemiological characteristics of adult and adolescent patients newly diagnosed with the human

- immunodeficiency virus at a Jamaican clinic for sexually transmitted infections. *West Indian Medical Journal*. 2005 Dec;54(6):360-3.
88. National HIV/STD Control Programme. National HIV/STI prevention and control program - Facts and figures - HIV/AIDS Epidemic Update January to December 2006. Kingston, Jamaica: Ministry of Health, Health Promotion and Protection Division; 2006 January to December 2006,.
89. Djumalieva D, Imamshah W, Wagner U, Razum O. Drug use and HIV risk in Trinidad and Tobago: qualitative study. *International Journal of STD & AIDS*. 2002 Sep;13(9):633-9.
90. Rodriguez C, M., Marques L, F., Touze G. HIV and injection drug use in Latin America. *AIDS*. 2002;16 Suppl 3:S34-41.
91. Sosa-Estani S, Rossi D, Weissenbacher M. Epidemiology of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome in injection drug users in Argentina: high seroprevalence of HIV infection. *Clinical Infectious Diseases*. 2003 Dec 15;37 Suppl 5:S338-42.
92. Weissenbacher M, Rossi D, Radulich G, Sosa-Estani S, Vila M, Vivas E, et al. High Seroprevalence of Bloodborne Viruses among Street-Recruited Injection Drug Users from Buenos Aires, Argentina. *Clinical Infectious Diseases*. 2003;37:S348-52.
93. Manzanero M. Email "IVDU Information Belize". In: Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW, editor. Reponse to request for data ed. Belmopan: National TB, HIV/AIDS and other STIs Programme: Belize; 2008.
94. Pan American Health Organization. *AIDS Surveillance in the Americas: Annual Report 2004*. Washington, D.C.; 2004.
95. Coordenação Nacional de DST e AIDS. *A Política do Ministério da Saúde Para a Atenção Integral a Usuários de Álcool e Outras Drogas*. Brasília: Ministério da Saúde; 2003.
96. Hacker MA, Malta M, Enriquez M, Bastos FI. Human immunodeficiency virus, AIDS, and drug consumption in South America and the Caribbean: epidemiological evidence and initiatives to curb the epidemic. *Revista Panamericana de Salud Pública*. 2005;18(4-5):303-13.
97. Pechansky F, Kessler F, Von Diemen L, Inciardi JA, Surratt H. Substance use, risk situations, and HIV seroprevalence among individuals seeking free HIV testing in Porto Alegre, Brazil. *Pan American Journal of Public Health*. 2005 Oct-Nov;18(4-5):249-55.
98. Pechansky F, Woody G, Inciardi J, Surratt H, Kessler F, Von Diemen L, et al. HIV seroprevalence among drug users: An analysis of selected variables based on 10 years of data collection in Porto Alegre, Brazil. (22 refs.). *Drug and Alcohol Dependence*. 2006;82(S1):S109-S13.
99. Consejo Nacional Para El Control De Estupefacientes (CONACE). *Septimo Estudio Nacional De Drogas En Poblacion General De Chile 2006*; Ministerio Del Interior, Gobierno De Chile, ; 2006.
100. Global Fund. *Acceleration and Improvement of the National, Intersectoral, Participative and Decentralized Response to the HIV/AIDS epidemic in Chile*. Chile: Country Coordinating Mechanism Chile,; 2002. p. 51.
101. Comision Nacional de Sida-Conasida. *Epidemiology of HIV/AIDS in Chile*. December 2003. *Revista Chilena de Infectologia*. 2005 Jun;22(2):169-202.
102. Soto RJ, Ghee AE, Nunez CA, Mayorga R, Tapia KA, Astete SG, et al. Sentinel Surveillance of Sexually Transmitted Infection/HIV and Risk Behaviors in Vulnerable Populations in 5 Central American Countries,. *Journal of Acquired Immune Deficiency Syndromes*,. 2007 September 46(1):101-11.

103. Persaud NE, Klaskala W, Tewari T, Shultz J, Baum M. Drug use and syphilis: Co-factors for HIV transmission among commercial sex workers in Guyana. *West Indian Medical Journal*. 1999 Jun;48(2):52-6.
104. Ramon JS, Alvarenga M, Walker N, Garcia-Calleja JM, Zacarias F. Estimating HIV/AIDS prevalence in countries with low-level and concentrated epidemics: the example of Honduras. *AIDS*. 2002 Dec;16(S3):S18-S22.
105. Bravo-García E, Magis-Rodríguez C, Saavedra J. New estimates in Mexico: more than 180,000 people living with HIV. XVI International AIDS Conference. Vancouver; 2006.
106. Frost SDW, Brouwer KC, Firestone Cruz MA, Ramos R, Ramos ME, Lozada RM, et al. Respondent-driven sampling of injection drug users in two U.S.-Mexico border cities: recruitment dynamics and impact on estimates of HIV and syphilis prevalence. *Journal of Urban Health: Bulletin of the New York Academy of Medicine*. 2006 Nov;83(S1):83-97.
107. Strathdee SA, Morgan MP, Semple S, Pu M, Orozovich P, Martinez G, et al. Correlates of injection drug use among female sex workers in two Mexico-U.S. border cities. *Drug and Alcohol Dependence*. 2007;9.
108. Programa nacional de Control de SIDA/ITS Paraguay (PRONASIDA). Estudio de ITSS (Infecciones de Transmisión Sexual Sanguínea) y Prácticas de riesgo en UDIs. 2006.
109. Programa nacional de Control de SIDA/ITS Paraguay (PRONASIDA). Estudio de Infecciones de Transmisión sanguínea y sexual y Prácticas de riesgo en Usuarios de Drogas inyectables en Paraguay Informe final.: Organización Panamericana de la Salud/Organización Mundial de la Salud; 2006.
110. National Anti-Drug Council Suriname. SURIDIN Suriname Drug Information Network. Annual National Report 2002. Paramaribo: National Anti-Drug Council Suriname; 2002 December 2002.
111. Woratanarat T. Global HIV cohort studies among injecting drug users and future vaccine trials. *J Med Assoc Thai*. 2006 Jul;89(7):1064-79.
112. UNAIDS. Report on the Global HIV/AIDS epidemic 2002. Geneva: Joint United Nations Programme on HIV/AIDS; 2002.
113. Ialomiteanu A. Email "Estimates of lifetime injecting drug use 15-64 years from the Canadian Addiction Survey 2004" In: Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW, editor. Response to request for data ed. Toronto: Centre for Addiction and Mental Health; 2008.
114. Public Health Agency of Canada. HIV/AIDS Epi Updates. August 2006. Ottawa: Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control Public Health Agency of Canada 2006 August 2006.
115. Glynn M, Rhodes P. Estimated HIV Prevalence in the United States at the end of 2003. National HIV Prevention Conference. Atlanta; 2005.
116. UNGASS. Country Report: Federated States of Micronesia: UNGASS; 2006.
117. World Health Organization. Second generation surveillance surveys of HIV, other STIs and risk behaviours in 6 Pacific Island countries (2004-2005). Manila, Philippines: World Health Organisation (WHO), Regional Office for the Western Pacific.; 2006 2006.
118. Pontali E. Email "Info for your Global report". In: Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW, editor. Response to request for data ed. Genoa: Galliera Hospital and Prison of Genoa; 2008.
119. Wang YA, Cliffe S, Toatu T, Tiban K, Black D, Sullivan E. Prevalence of STI, HIV and risk behaviors among seafarers in Kiribati 2005. XIV International AIDS Conference. Toronto; 2006.
120. McDonald D. A rapid situation assessment of drug use in Papua New Guinea. *Drug and Alcohol Review*. 2005;24(1):79-82.

121. AusAID. Impacts of HIV/AIDS 2005-2025 in Papua New Guinea, Indonesia and East Timor: Final Report of HIV Epidemiological Modelling and Impact Study. Canberra: Department of Foreign Affairs and Trade; 2006.
122. McBride W. HIV/AIDS in Papua New Guinea: An unfolding disaster? *Emergency Medicine Australasia*. 2005;17(4):304-6.
123. Razali K, Thein H, Bell J, Cooper-Stanbury M, Dolan K, Dore G, et al. Modelling the hepatitis C virus epidemic in Australia. *Drug and Alcohol Dependence*. 2007;91(2-3):228-35.
124. National Centre in HIV Epidemiology and Clinical Research. Australian NSP Survey National Data Report 2003-2007: Prevalence of HIV, HCV and Injecting and Sexual Behaviour among IDUs at needle and syringe programs. Sydney: The University of New South Wales;; 2008.
125. Wilkins C, Girling M, Sweetsur P. Recent trends in drug use in New Zealand: 2006. Auckland: Massey University; 2006.
126. UNAIDS. 2006 AIDS Epidemic Update: Middle East and North Africa. Geneva: Joint United Nations Programme on HIV/AIDS; 2006.
127. MESRS. Etude du lien potentiel entre usage problématique de drogues et VIH/SIDA en Algérie. Algeria: UNAIDS; 2006.
128. Jenkins C, Robalino DA. HIV/AIDS in the Middle East and North Africa: The Costs of Inaction. Washington, D.C.: The World Bank; 2003.
129. World Bank. Preventing HIV/AIDS in the Middle East and North Africa: A Window of Opportunity to Act. Washington, D.C.: World Bank; 2005.
130. European Monitoring Centre for Drugs and Drug Addiction & Reitox National Focal Point. Cyprus: New Developments, Trends and in-depth information on selected issues. Lisbon: EMCDDA; 2006.
131. Dewing S, Plüddemann A, Myers B, J., Parry CDH. Review of injection drug use in six African countries: Egypt, Kenya, Mauritius, Nigeria, South Africa and Tanzania. *Drugs: Education, Prevention and Policy*. 2006;13(2):121-37.
132. Grotherath A. Drug abuse and HIV/AIDS in the Middle East and North Africa: a situation assessment: UNODCCP, UNAIDS; 2002.
133. Elshimi T, Warner-Smith M, Aon M. HIV risk-behaviours of problem drug users in greater Cairo Cairo: United Nations Office of Drugs and Crime;; 2004.
134. Peles E, Schreiber S, Adelson M. Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. *Drug & Alcohol Dependence*. 2006 May 20;82(3):211-7.
135. AIDS Projects Management Group. Recommendations for interventions addressing injecting drug use and related HIV infection in Egypt. Sydney: AIDS Projects Management Group;; 2007. p. 25.
136. Isralowitz R, Reznik A, Spear SE, Brecht ML, Rawson RA. Severity of heroin use in Israel: Comparisons between native Israelis and former Soviet Union immigrants. 2007;102(4):630-7.
137. Gekopf M, Weizman T, Melamed Y, Adelson M, Bleich A. Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic. *Israel Journal of Psychiatry and Related Sciences*. 2006;43(2):126-36.
138. Global Fund. Grant Performance Report: Maintaining low HIV prevalence among the population and all vulnerable subpopulations in Jordan. Jordan; 2007. p. 11.
139. Global Fund. Proposal Form Sixth Call for Proposals: Maintaining Low HIV prevalence among the population and all vulnerable sub-populations in Jordan. Jordan; 2006. p. 77.
140. United Nations Office on Drugs and Crime & Institute for Development Research and Applied Care. Substance Use and Misuse in Lebanon. Beirut: UNODC & IDRAC; 2003 May 2003.

141. Toufik A. VIH/Drogues MENA. Paris, France: Observatoire français des drogues et des toxicomanies; 2006.
142. Global Fund. Sixth Call for Proposals of the Global Fund to fight AIDS, Tuberculosis and Malaria: Proposal of the CCM for Morocco. HIV/AIDS and Tuberculosis Components. Kingdom of Morocco; 2006. p. 119.
143. Madani TA, Al-Mazrou YY, Al-Jeffri MH, Al Huzaim NS. Epidemiology of the human immunodeficiency virus in Saudi Arabia; 18-year surveillance results and prevention from an Islamic perspective. *BMC Infectious Diseases*. 2004 Aug 6;4:25.
144. Global Fund. Sixth Call for Proposals: Support for Partnership and Strengthening of the Response to the Threat of the Spread of HIV/AIDS in Tunisia. Republic of Tunisia, Ministry of Health. Country Coordinating Mechanism; 2006. p. 122.
145. Kavasoglu E. Email "YNT: Annual Reports Questionnaires (ARQ)". In: Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW, editor. Reponse to request for data ed. Ankara: Ministry of Health; 2008.
146. Beckerleg S, Telfer M, Sadiq A. A Rapid Assessment of Heroin Use in Mombasa, Kenya. *Substance Use & Misuse*. 2006;41(6-7):1029-44.
147. Beckerleg S, Lewando Hundt G. The characteristics and recent growth of heroin injecting in a Kenyan coastal town. *Addiction Research & Theory*. 2004;12(1):41-53.
148. AIDS Projects Management Group. Is There Anyone Left in the General Population: A Scan of Information Available on the Context of HIV Transmission and Risk for Vulnerable Groups in Seventeen Countries with Concentrated HIV Epidemics. Sydney: AIDS Projects Management Group, ; 2005 20 August 2005.
149. Odek-Ogunde M, Okoth FA, Lore W, Owiti FR. Seroprevalence of HIV, HBC and HCV in injecting drug users in Nairobi, Kenya: World Health Organization Drug Injecting Study Phase II findings,. International Conference on AIDS July 11-14 2004. Bangkok, Thailand; 2004.
150. Ndetei DM. A study on the linkages between drug abuse, injecting drug abuse and HIV/AIDS in Kenya: A rapid situation assessment 2004: United Nations Office on Drugs and Crime 2004.
151. Bisika T, Konyani S, Chamangwana I. Rapid Situation Assessment of Drug Abuse and HIV/AIDS in Malawi. Malawi: The Ministry of Home Affairs and Internal Security, Inter-Ministerial Committee on Capacity Building for Drug Control Project; 2004.
152. Abdool R, Sulliman FT, Dhannos MI. The injecting drug use and HIV/AIDS nexus in the Republic of Mauritius *African Journal of Drug & Alcohol Studies*,. 2006;5(2):9.
153. Sulliman F, Ameerberg SAG, Dhannoo MI. Report of the Rapid Situation Assessment and Resonances on Drug Use in Mauritius & Rodrigues. Port Louis: Ministry of Health, Mauritius.; 2004.
154. Adelekan ML, Lawal RA. Drug Use and HIV Infection in Nigeria: A review of recent findings. *African Journal of Drug & Alcohol Studies*,. 2006;5(2):12.
155. Lawal RA. A rapid situation assessment and response study of drug use, injecting drug use, HIV/AIDS and other risk behaviors among drug users targeting five Nigerian cities. Vienna: UNODC; 2006.
156. Kalichman SC, Simbayi LC, Kagee A, Toefy Y, Jooste S, Cain D, et al. Associations of poverty, substance use, and HIV transmission risk behaviors in three South African communities. *Social Science and Medicine*. 2006 Apr;62(7):1641-9.
157. Parry CDH, Carney T, Petersen P, Dewing S, Needle R. HIV risk behavior in South African drug users: A tale of three cities. *Alcohol & Drug Abuse Research Unit, Medical Research Council South Africa*.; 2007. p. 30.
158. Parry C, Nwanyanwu O, Needle R, Achrekar A. HIV and Drug Use Among Injection Drug Users (IDUs), Commercial Sex Workers (CSWs), and Men who have Sex

- with Men (MSM) in South Africa. The President's Emergency Plan for AIDS Relief Annual Meeting: The 2006 HIV/AIDS Implementers' Meeting. Durban; 2006.
159. Williams ML, McCurdy SA, Atkinson JS, Kilonzo GP, Leshabari MT, Ross MW. Differences in HIV Risk Behaviors by Gender in a Sample of Tanzanian Injection Drug Users. *AIDS and Behavior*. 2007;11(1):137-44.
160. Timpson S, et al. Substance Abuse, HIV Risk and HIV/AIDS in Tanzania. *African Journal of Drug & Alcohol Studies*. 2006;5(2):158-69.
161. McCurdy SA, Ross MW, Gad PK, Leshabari MT, Williams ML. HIV/AIDS and injection drug use in the neighborhoods of Dar es Salaam, Tanzania. *Drug and Alcohol Dependence*. 2006;82(S1):S23-S7.
162. Dahoma M, Salim A, Abdool R, Othman A, Makame H, Ali S, et al. HIV and Substance Abuse: the dual epidemics challenging Zanzibar. *African Journal of Drug & Alcohol Studies*. 2006;5(2):130-9.
163. McCurdy A, Williams M, Kilonzo G, Ross M, Leshabari M. Heroin and HIV risk in Dar es Salaam, Tanzania: Youth hangouts, mageto and injecting practices. *AIDS Care*. 2005;17(1):65-78.